Cinaciguat prevents the development of pathologic hypertrophy in a rat model of left ventricular pressure overload
Open Access
- 17 November 2016
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 6 (1) , 37166
Abstract
Pathologic myocardial hypertrophy develops when the heart is chronically pressure-overloaded. Elevated intracellular cGMP-levels have been reported to prevent the development of pathologic myocardial hypertrophy, therefore we investigated the effects of chronic activation of the cGMP producing enzyme, soluble guanylate cyclase by Cinaciguat in a rat model of pressure overload-induced cardiac hypertrophy. Abdominal aortic banding (AAB) was used to evoke pressure overload-induced cardiac hypertrophy in male Wistar rats. Sham operated animals served as controls. Experimental and control groups were treated with 10 mg/kg/day Cinaciguat (Cin) or placebo (Co) p.o. for six weeks, respectively. Pathologic myocardial hypertrophy was present in the AABCo group following 6 weeks of pressure overload of the heart, evidenced by increased relative heart weight, average cardiomyocyte diameter, collagen content and apoptosis. Cinaciguat did not significantly alter blood pressure, but effectively attenuated all features of pathologic myocardial hypertrophy, and normalized functional changes, such as the increase in contractility following AAB. Our results demonstrate that chronic enhancement of cGMP signalling by pharmacological activation of sGC might be a novel therapeutic approach in the prevention of pathologic myocardial hypertrophy.Keywords
This publication has 55 references indexed in Scilit:
- Physiological and pathological left ventricular hypertrophy of comparable degree is associated with characteristic differences of in vivo hemodynamicsAmerican Journal of Physiology-Heart and Circulatory Physiology, 2016
- Meta-Analysis of Large-Scale Randomized Trials to Determine the Effectiveness of Inhibition of the Renin-Angiotensin Aldosterone System in Heart FailureThe American Journal of Cardiology, 2015
- The Soluble Guanylyl Cyclase Activator Bay 58-2667 Selectively Limits Cardiomyocyte HypertrophyPLOS ONE, 2012
- Cinaciguat, a Soluble Guanylate Cyclase Activator: Results from the Randomized, Controlled, Phase IIb COMPOSE Programme in Acute Heart Failure SyndromesEuropean Journal of Heart Failure, 2012
- Rescue of Ca2+ overload-induced left ventriclur dysfunction by targeted ablation of phospholambanAmerican Journal of Physiology-Heart and Circulatory Physiology, 2009
- DIFFERENCES BETWEEN PATHOLOGICAL AND PHYSIOLOGICAL CARDIAC HYPERTROPHY: NOVEL THERAPEUTIC STRATEGIES TO TREAT HEART FAILUREClinical and Experimental Pharmacology and Physiology, 2007
- NO‐independent activation of soluble guanylate cyclase prevents disease progression in rats with 5/6 nephrectomyBritish Journal of Pharmacology, 2006
- New Concepts in Diastolic Dysfunction and Diastolic Heart Failure: Part IICirculation, 2002
- Effect of angiotensin II receptor antagonism on vascular hypertrophy and aortic impedance in abdominal aortic-banded ratAmerican Journal of Hypertension, 1999
- Use of tibial length to quantify cardiac hypertrophy: application in the aging ratAmerican Journal of Physiology-Heart and Circulatory Physiology, 1982